| Erin Kennedy, LPN | |
|
123 S. Webb Rd., Grand Island, NE 68802 | |
| (308) 385-5900 | |
| Not Available |
| Full Name | Erin Kennedy |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 123 S. Webb Rd., Grand Island, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689167728 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 23882 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Erin Kennedy, LPN 123 S. Webb Rd., Grand Island, NE 68802 Ph: () - | Erin Kennedy, LPN 123 S. Webb Rd., Grand Island, NE 68802 Ph: (308) 385-5900 |
News Archive
As the COVID-19 pandemic and its far-reaching implications continue to unfold globally and disrupt our normal way of life, scientists and researchers are racing to find an appropriate vaccine or therapeutic drug. This process involves understanding how the virus interacts with the host cell, the dynamics of the host immune response, and the eventual outcome.
Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen and other gas delivery, today announced that the European Commission (EC) has granted orphan medicinal product designation for MP4CO for the treatment of sickle cell disease.
"Malnutrition is likely to be the most serious health threat linked to climate shifts in the coming decades, as farmers struggle to cope with more unpredictable weather, ... epidemiologist Kris Ebi warned during a recent World Health Organization (WHO) briefing on adapting health systems to climate shifts," AlertNet reports.
Pfizer Inc. announced today top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079), evaluating the efficacy and safety of tofacitinib, an oral Janus kinase (JAK) inhibitor, the first in a new class of medicines being investigated for the treatment of moderate-to-severe plaque psoriasis.
› Verified 1 days ago
Angela Hagedorn, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 123 S. Webb Rd., Grand Island, NE 68802 Phone: 308-385-5900 | |
Chelsea Powell, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 123 S Webb Rd, Grand Island, NE 68803 Phone: 308-385-5900 | |
Monti Starkey, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 123 S. Webb Rd., Grand Island, NE 68802 Phone: 308-385-5900 | |
Tammy Marie Kuhl, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 2710 N North Rd, Grand Island, NE 68803 Phone: 308-385-6394 | |
Amanda Kirkland, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 123 S. Webb Rd., Grand Island, NE 68802 Phone: 308-385-5900 | |
Abbie Kelley, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 123 S. Webb Rd., Grand Island, NE 68802 Phone: 308-385-5900 | |
Elizabeth A. Peterson, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 123 S Webb Rd, Grand Island, NE 68803 Phone: 308-385-5900 |